Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (19)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Sweeney, C. J.
Right arrow Articles by Einhorn, L. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sweeney, C. J.
Right arrow Articles by Einhorn, L. H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 13:435-440, 2002
© 2002 European Society for Medical Oncology

A phase II Hoosier Oncology Group study of vinorelbine and estramustine phosphate in hormone-refractory prostate cancer

C. J. Sweeney, F. J. Monaco, S.-H. Jung, M. J. Wasielewski, J. Picus, R. H. Ansari, W. M. Dugan and L. H. Einhorn+

Hoosier Oncology Group, 3202 North Meridian, Indianapolis IN, USA

Received 19 April 2001; revised 3 August 2001; accepted 6 September 2001.

Background

The purpose was to evaluate the combined anti-microtubular regimen of vinorelbine and estramustine phosphate (EMP) in hormone refractory prostate cancer.

Patients and methods

Weekly vinorelbine 20 mg/m2 (or 15 mg/m2 if a history of prior pelvic radiotherapy) was combined with EMP at 280 mg orally tds for 3 days (the day before, the day of and the day after vinorelbine infusion). After 8 weeks of therapy the combination was given every other week.

Results

From February 1998 to February 1999, 23 men were enrolled with a median age of 69 years (range 50–83 years). The median prostate-specific antigen (PSA) at entry was 160 ng/ml (range 0–802 ng/ml). A median of 13 weeks of therapy was administered and the median follow-up was 14.8 months. Eleven patients (48%) had lower extremity edema requiring diuretic therapy, two (9%) had grade 2 granulocytopenia and four patients [17%; 95% confidence interval (CI) 5% to 39%] had a thromboembolic episode. There was no treatment-related mortality. Fifteen of 21 patients (71%; 95% CI 49% to 89%) had at least a 50% decrease in the PSA for at least 2 months with a median time to serologic progression of 3.5 months (range 0.75–10.5 months). One of eight patients (12.5%; 95% CI 0% to 53%) with measurable disease had a confirmed partial response. The estimated median survival was 15.1 months and the actual one year overall survival was 71% (95% CI 51% to 88%).

Conclusions

Weekly vinorelbine with short course oral EMP is an active regimen as evaluated by rate of PSA response, time to progression and median survival. However, the toxicities of EMP, even when given as a short course, are still problematic.

Key words: estramustine, hormone refractory prostate cancer, vinorelbine


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Anticancer ResHome page
D. PECTASIDES, E. PECTASIDES, G. PAPAXOINIS, A. KOUMARIANOU, A. PSYRRI, N. XIROS, N. TOUNTAS, K. KAMPOSIORAS, G. PAPATSIBAS, T. FLOROS, et al.
Combination Chemotherapy with Docetaxel, Vinorelbine and Estramustine Phosphate in Metastatic Androgen-resistant Prostate Cancer: A Single Institution Experience
Anticancer Res, February 1, 2009; 29(2): 769 - 775.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
N. M. Hahn, S. Marsh, W. Fisher, R. Langdon, R. Zon, M. Browning, C. S. Johnson, T. J. Scott-Horton, L. Li, H. L. McLeod, et al.
Hoosier Oncology Group Randomized Phase II Study of Docetaxel, Vinorelbine, and Estramustine in Combination in Hormone-Refractory Prostate Cancer with Pharmacogenetic Survival Analysis.
Clin. Cancer Res., October 15, 2006; 12(20): 6094 - 6099.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
W.-C. Sheen, J.-S. Chen, H.-M. Wang, T.-S. Yang, C.-C. Liaw, and Y.-C. Lin
A Modified Low-dose Regimen of Mitoxantrone and Prednisolone in Patients with Androgen-independent Prostate Cancer
Jpn. J. Clin. Oncol., June 1, 2004; 34(6): 337 - 341.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.